Glenmark Pharmaceuticals Q4 Results: Net dips 26% to Rs 173 cr

Consolidated revenues of the drug firm, however, rose to Rs 3,019 crore in the quarter under review as compared to Rs 2,860 crore in the year-ago period, recording an increase of 6 per cent year-on-year.

Related Keywords

Mumbai ,Maharashtra ,India ,Glenn Saldanha ,Glenmark Lifesciences ,Glenmark Pharmaceuticals ,Glenmark Pharmaceuticals On ,Pharmaceuticals Chairman ,Managing Director Glenn Saldanha ,Glenmark Pharmaceuticals News ,Lenmark Pharmaceuticals Q4 Results ,Lenmark Pharmaceuticals Q4 Earnings ,